Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
2020 · Acta Pharmaceutica Sinica B · 139 citations
https://doi.org/10.1016/j.apsb.2020.05.001
K
Kai Yuan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
44
Papers
793
Citations
15
h-index
22
i10-index
Kai Yuan is an academic researcher from China Pharmaceutical University. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Cancer Immunotherapy and Biomarkers & Cancer-related Molecular Pathways. The author has an h-index of 15, co-authored 38 publications.
ORCID: 0000-0002-3030-6460Papers by this author
worksBispecific antibodies in cancer therapy: Target selection and regulatory requirements
2023 · Acta Pharmaceutica Sinica B · 79 citations
https://doi.org/10.1016/j.apsb.2023.05.023
Evaluation of an enzyme-linked immunospot assay for the immunodiagnosis of atypical spinal tuberculosis (atypical clinical presentation/atypical radiographic presentation) in China
2013 · The Brazilian Journal of Infectious Diseases · 10 citations
https://doi.org/10.1016/j.bjid.2013.01.013
Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment
2025 · Chinese Journal of Natural Medicines · 8 citations
https://doi.org/10.1016/s1875-5364(25)60846-6
The synergistic effect of biosynthesized CuONPs and phage (ϕPB2) as a novel approach for controlling Ralstonia solanacearum
2024 · Chemical and Biological Technologies in Agriculture · 4 citations
https://doi.org/10.1186/s40538-024-00630-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat